Induction of cell cycle arrest and apoptosis in myeloma cells by cepharanthine, a biscoclaurine alkaloid

International Journal of Oncology

Volumn 33, Issue 4, 2008, Pages 807-814

  Kikukawa, Yoshitaka ^a   Okuno, Yutaka ^a   Tatetsu, Hiro ^a   Nakamura, Miki ^a   Harada, Naoko ^a   Ueno, Shikiko ^a   Kamizaki, Yorinori ^b   Mitsuya, Hiroaki ^a   Hata, Hiroyuki ^a  

^a KUMAMOTO UNIVERSITY HOSPITAL   (Japan)

^b Yatsushiro General Hospital   (Japan)

Author keywords

Alkaloid; Apoptosis; CDK inhibitors; Multiple myeloma; Reactive oxygen species

Indexed keywords

ALKALOID DERIVATIVE; BETAMETHASONE; CASPASE 3; CASPASE INHIBITOR; CEPHARANTHINE; CYCLIN DEPENDENT KINASE INHIBITOR; DEXAMETHASONE; MELPHALAN; PREDNISOLONE; REACTIVE OXYGEN METABOLITE; SCAVENGER; THALIDOMIDE; TIRON;

AGED; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER INHIBITION; CANCER STAGING; CASE REPORT; CELL CYCLE ARREST; CELL CYCLE PROGRESSION; CLINICAL EFFECTIVENESS; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG DOSE REDUCTION; DRUG EXPOSURE; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EDEMA; ENZYME ACTIVATION; FEMALE; HUMAN; HUMAN CELL; IN VITRO STUDY; MONOTHERAPY; MULTIPLE MYELOMA; MYELOMA CELL; PRIORITY JOURNAL; PROTEIN SYNTHESIS; STRUCTURE ACTIVITY RELATION; SUDDEN DEAFNESS; THROMBOCYTOPENIA; TUMOR VOLUME;

AGED; ALKALOIDS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; APOPTOSIS; BENZYLISOQUINOLINES; CASPASES; CELL CYCLE; CELL LINE, TUMOR; DOSE-RESPONSE RELATIONSHIP, DRUG; ENZYME INHIBITORS; FEMALE; HUMANS; MULTIPLE MYELOMA; PROGNOSIS; REACTIVE OXYGEN SPECIES;

EID: 54049087378     PISSN: 10196439     EISSN: None     Source Type: Journal    
DOI: 10.3892/ijo_00000068     Document Type: Article

References (37)

1. Anderson KC, Hannah AL, Pazdur R and Farrell AT: A strategic framework for novel drug development in multiple myeloma. Br J Haematol 138: 153-159, 2007.
2. Richardson PG, Mitsiades C, Schlossman R, Munshi N and Anderson K: New drugs for myeloma. Oncologist 12: 664-689, 2007.
3. Tomita M, Fujitani K and Aoyagi Y: Synthesis of dl-cepharanthine. Tetrahedron Lett 13: 1201-1206, 1967.
4. Nemoto K, Yoshida K, Nisimura M and Seki M: The effects of Cepharanthin on the recovery of hematopoietic stem cells after X-ray irradiation. Gan To Kagaku Ryoho 18: 81-84, 1991.
5. Takahashi K, Shinozuka T, Kiuchi K, et al: Cepharanthine therapy of alopecia. C R Seances Soc Biol Fil 150: 1844-1845, 1956.
6. Furusawa S and Wu J: The effects of biscoclaurine alkaloid cepharanthine on mammalian cells: implications for cancer, shock, and inflammatory diseases. Life Sci 80: 1073-1079, 2007.
7. Azuma M, Aota K, Tamatani T, et al: Suppression of tumor necrosis factor alpha-induced matrix metalloproteinase 9 production in human salivary gland acinar cells by cepharanthine occurs via down-regulation of nuclear factor kappaB: a possible therapeutic agent for preventing the destruction of the acinar structure in the salivary glands of Sjogren's syndrome patients. Arthritis Rheum 46: 1585-1594, 2002.
8. Sumizawa T, Chen ZS, Chuman Y, et al: Reversal of multidrug resistance-associated protein-mediated drug resistance by the pyridine analog PAK-104P. Mol Pharmacol 51: 399-405, 1997.
9. Aogi K, Nishiyama M, Kim R, et al: Overcoming CPT-11 resistance by using a biscoclaurine alkaloid, cepharanthine, to modulate plasma trans-membrane potential. Int J Cancer 72: 295-300, 1997.
10. Kitazono M, Okumura H, Ikeda R, et al: Reversal of LRP-associated drug resistance in colon carcinoma SW-620 cells. Int J Cancer 91: 126-131, 2001.
11. Murakami K, Cox RA, Hawkins HK, et al: Cepharanthin, an alkaloid from Stephania cepharantha, inhibits increased pulmonary vascular permeability in an ovine model of sepsis. Shock 20: 46-51, 2003.
12. Ikeda R, Che XF, Yamaguchi T, et al: Cepharanthine potently enhances the sensitivity of anticancer agents in K562 cells. Cancer Sci 96: 372-376, 2005.
13. Nakajima A, Yamamoto Y, Taura K, et al: Beneficial effect of cepharanthine on overcoming drug-resistance of hepatocellular carcinoma. Int J Oncol 24: 635-645, 2004.
14. Katsui K, Kuroda M, Wang Y, et al: Cepharanthin enhances adriamycin sensitivity by synergistically accelerating apoptosis for adriamycin-resistant osteosarcoma cell lines, SaOS2-AR and SaOS2 F-AR. Int J Oncol 25: 47-56, 2004.
15. Kono K, Takahashi JA, Ueba T, Mori H, Hashimoto N and Fukumoto M: Effects of combination chemotherapy with biscoclaurine-derived alkaloid (Cepharanthine) and nimustine hydrochloride on malignant glioma cell lines. J Neurooncol 56: 101-108, 2002.
16. Tamatani T, Azuma M, Motegi K, Takamaru N, Kawashima Y and Bando T: Cepharanthin-enhanced radiosensitivity through the inhibition of radiation-induced nuclear factor-kappaB activity in human oral squamous cell carcinoma cells. Int J Oncol 31: 761-768, 2007.
17. Harada K, Supriatno, Yamamoto S, Kawaguchi S, Yoshida H and Sato M: Cepharanthine exerts antitumor activity on oral squamous cell carcinoma cell lines by induction of p27Kip1. Anticancer Res 23: 1441-1448, 2003.
18. Wu J, Suzuki H, Akhand AA, Zhou YW, Hossain K and Nakashima I: Modes of activation of mitogen-activated protein kinases and their roles in cepharanthine-induced apoptosis in human leukemia cells. Cell Signal 14: 509-515, 2002.
19. Satoh K, Nagai F, Ono M and Aoki N: Inhibition of Na(+), K(+)-ATPase by the extract of Stephania cephararantha HAYATA and bisbenzylisoquinoline alkaloid cycleanine, a major constituent. Biochem Pharmacol 66: 379-385, 2003.
20. Biswas KK, Tancharoen S, Sarker KP, Kawahara K, Hashiguchi T and Maruyama I: Cepharanthine triggers apoptosis in a human hepatocellular carcinoma cell line (HuH-7) through the activation of JNK1/2 and the downregulation of Akt. FEBS Lett 580: 703-710, 2006.
21. Fujimura T, Furusawa S, Kawauchi H, Takayanagi Y and Sasaki K: Effect of cepharanthine on doxorubicin cytotoxicity in P388 murine leukemia cells in vitro and in vivo. Res Commun Chem Pathol Pharmacol 71: 235-238, 1991.
22. Morikawa K, Oseko F and Morikawa S: Inhibition of proliferation and differentiation of human B-lymphocytes by a biscoclaurine alkaloid. Int J Immunopharmacol 14: 941-949, 1992.
23. Wu J, Suzuki H, Zhou YW, et al: Cepharanthine activates caspases and induces apoptosis in Jurkat and K562 human leukemia cell lines. J Cell Biochem 82: 200-214, 2001.
24. Saito N, Takemori N, Hirai K, Onodera R, Watanabe S and Kohgo Y: High-dose biscoclaurine alkaloids together with prednisolone raise platelet counts in chronic idiopathic thrombocytopenic purpura. Am J Hematol 51: 173-174, 1996.
25. Kobayashi M, Katayama T, Ochiai S, et al: High-dose cepharanthin therapy of idiopathic thrombocytopenic purpura. Rinsho Ketsueki 33: 405-407, 1992.
26. Ohtsuki T, Yawata Y, Wada H, Sugihara T, Mori M and Namba M: Two human myeloma cell lines, amylase-producing KMS-12-PE and amylase-non-producing KMS-12-BM, were established from a patient, having the same chromosome marker,t(11;14)(q13;q32). Br J Haematol 73: 199-204, 1989.
27. Carini C, Hudspith BN and Brostoff J: Effect of prostaglandins and cyclic nucleotides on growth and immunoglobulin secretion of two IgE myeloma cell lines. Br J Cancer 43: 257-260, 1981.
28. Togawa A, Inoue N, Miyamoto K, Hyodo H and Namba M: Establishment and characterization of a human myeloma cell line (KMM-1). Int J Cancer 29: 495-500, 1982.
29. Hata H, Matsuzaki H, Sonoki T, et al: Establishment of a CD45-positive immature plasma cell line from an aggressive multiple myeloma with high serum lactate dehydrogenase. Leukemia 8: 1768-1773, 1994.
30. Hamburger AW, Kim MB and Salmon SE: The nature of cells generating human myeloma colonies in vitro. J Cell Physiol 98: 371-376, 1979.
31. Harada N, Nagasaki A, Hata H, Matsuzaki H, Matsuno F and Mitsuya H: Down-regulation of CD98 in melphalan-resistant myeloma cells with reduced drug uptake. Acta Haematol 103: 144-151, 2000.
32. Harada K, Bando T, Yoshida H and Sato M: Characteristics of antitumour activity of cepharanthin against a human adenosquamous cell carcinoma cell line. Oral Oncol 37: 643-651, 2001.
33. Furusawa S, Wu J, Fujimura T, et al: Cepharanthine inhibits proliferation of cancer cells by inducing apoptosis. Methods Find Exp Clin Pharmacol 20: 87-97, 1998.
34. Akamatsu H, Komura J, Asada Y and Niwa Y: Effects of cepharanthin on neutrophil chemotaxis, phagocytosis, and reactive oxygen species generation. J Dermatol 18: 643-648, 1991.
35. Wang Y, Kuroda M, Gao XS, et al: Cepharanthine enhances in vitro and in vivo thermosensitivity of a mouse fibrosarcoma, FSa-II, based on increased apoptosis. Int J Mol Med 13: 405-411, 2004.
36. Hotta T, Tanimura H, Yamaue H, et al: Modulation of multidrug resistance by cepharanthine in fresh human gastrointestinal tumor cells. Oncology 54: 153-157, 1997.
37. Zhao XY, He ZW, Wu D and Xu RZ: Berbamine selectively induces apoptosis of human acute promyelocytic leukemia cells via survivin-mediated pathway. Chin Med J (Engl) 120: 802-806, 2007.